KEYNOTE-024 data presentation
KEYTRUDA® (pembrolizumab) vs. chemotherapy for PD-L1 TPS ≥50% non-small cell lung cancer
Prescribing Information [External link]
Download our KEYNOTE-024 slide deck that discusses KEYTRUDA vs chemotherapy for PD-L1 TPS ≥50% non-small cell lung cancer.
Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@msd.com, Phone: 0208 154 8000).
More information about KEYTRUDA in metastatic NSCLC:
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
